A Phase 3 interventional study of Tranexamic Acid in Bleeding, Surgical Blood Loss and Seizures, sponsored by Population Health Research Institute. Terminated at 16 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Population Health Research Institute · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing Tranexamic Acid in Blood Loss, Surgical — 9 open to participants now, 9 under way, 4 of them phase 3. Tranexamic Acid · Blood Loss, Surgical.
Among the 46 studies testing Tranexamic Acid in Blood Loss, Surgical, this one has the largest enrollment, is one of 6 that started in 2019, is one of 9 in phase 3, and was the 20th registered.
213 studies on the registry are indexed under Blood Loss, Surgical; 40 are open to participants now.
Browse Blood Loss, Surgical studies →9 of the 46 studies testing Tranexamic Acid in Blood Loss, Surgical are open now, in 6 countries. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 2–17
Wolfson Medical Center · Sites in Israel
Ages 18–51 · Women only · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 2–17
Assiut University · Sites in Egypt
Ages 18–65 · Healthy volunteers
University of Virginia · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →
Of the 27 Blood Loss, Surgical studies recruiting now, 10 (37%) set no upper age limit and 14 (52%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6 · Phase 3 12 · Phase 4 18
First in 2007; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,242 is above the median of 80 across 160 interventional studies indexed under Blood Loss, Surgical.
Median enrollment 98 across the 46 interventional studies. Of the 27 that completed or were terminated, 8 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 46 have an industry lead sponsor. The 10 most frequent:
Population Health Research Institute is the lead sponsor of 115 studies on the registry; 26 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Population Health Research Institute has 2 studies filed under Blood Loss, Surgical — fewer than ten, so there is no comparison to draw.
3 of the studies testing Tranexamic Acid in Blood Loss, Surgical that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03553186Phase 3Hospital for Special Surgery, New YorkTranexamic Acid in Adult Spinal Deformity Surgery | 2027-03 |
| NCT07565753The University of Texas Health Science Center at San AntonioTEAPOT Study Multisite | 2027-09-30 |
| NCT06580509The University of Texas Health Science Center at San AntonioTranExamic Atomized for Pediatric Post-Operative Tonsillectomy Hemorrhage: Pilot Study | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 46 studies testing Tranexamic Acid in Blood Loss, Surgical, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim is to conduct a double-dummy multi-centre randomized controlled clinical trial of application of topical dose of tranexamic acid (TxA) versus the usual intravenous TxA in patients undergoing on-pump cardiac surgery.
Postoperative bleeding related to open cardiac surgery increases the rates of complications and mortality. It results from the blood thinners that are needed for use. Intravenous tranexamic acid (TxA) has become a mainstay in cardiac surgical procedures for decreasing bleeding and minimizing transfusion requirements. Although intravenous TxA is usually well tolerated, there is a well-known risk (1 to 4%) of postoperative seizures. This is due to the similarity between TxA and the brain tissues. The aim is to eliminate the risk of seizures but to maintain the protection against bleeding. When TxA is used directly on the tissues (topically) for other type of surgeries (joints), TxA is effective to reduce blood loss and transfusions. The aim is to prove that direct application of TxA on the heart can eliminate postoperative seizures and reduce the amount of blood transfusions in patients who have cardiac surgery.
213 studies on the registry are indexed under Blood Loss, Surgical; 40 are open to participants now.
This study's enrollment of 3,242 is above the median of 80 across 160 interventional studies indexed under Blood Loss, Surgical.
Browse Blood Loss, Surgical studies →Population Health Research Institute is the lead sponsor of 115 studies on the registry; 26 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Compared within Blood Loss, Surgical, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hemorrhage. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Fulfill any of the following transfusion risk factors (A-D):
A. Emergency surgery B. History of bleeding disorder C. Inherited thromboembolic or hemorrhagic disease D. Infective endocarditis (active)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Topical Tranexamic Acid 5g to 10g (50 to 100mL) or placebo. The topical will be poured into the pericardial and mediastinal cavities after protamine administration.
Drug: Tranexamic Acid
Intravenous Tranexamic Acid 1 to 10g (10 to 100mL) or placebo administered intravenously at the induction of anesthesia as a bolus-infusion.
Drug: Tranexamic Acid
Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
Also known as: Cyklokapron
The Proportion of Patients Experiencing an In-hospital Seizure
To determine in patients undergoing on-pump cardiac surgery, if topical tranexamic acid (intra-pericardial) is superior to the usual intravenous tranexamic acid administration for reducing the risk of in-hospital seizure.
Time frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
The Proportion of Patients In-hospital Who Receive Red Blood Cell Transfusions
To determine in patients undergoing on-pump cardiac surgery, if topical tranexamic acid (intra-pericardial) compared with intravenous tranexamic acid administration is associated with a non-inferior risk of in-hospital red blood cell transfusion.
Time frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
Blood Product Transfusions
Analyzed using an ANCOVA model. In such a model, bags of blood product will be included as a dependent variable, whereas dose of tranexamic acid and treatment will be included as covariates.
Time frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
Re-operation for Bleeding or Tamponade
Analyzed with a binomial regression
Time frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
Duration of ICU Stay
Analyzed using an ANCOVA model.
Time frame: Number of hours in ICU are being collected at the Post-Operative Visit. Hour collection will start upon arrival at ICU post surgery and stop at ICU exit, up to 10 days maximum.
MACE (Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke)
A Cox proportional hazard model will be used to analyze the time to the first occurrence of the composite of death, non-fatal MI, or non-fatal stroke (MACE).
Time frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
| Milestone | Topical Tranexamic Acid/Placebo | Intravenous Tranexamic Acid/Placebo |
|---|---|---|
| Started | 1624 | 1618 |
| Completed | 1624 | 1618 |
| Not completed | 0 | 0 |
To determine in patients undergoing on-pump cardiac surgery, if topical tranexamic acid (intra-pericardial) is superior to the usual intravenous tranexamic acid administration for reducing the risk of in-hospital seizure.
| Participants | Topical Tranexamic Acid/Placebo | Intravenous Tranexamic Acid/Placebo |
|---|---|---|
| The Proportion of Patients Experiencing an In-hospital Seizure | 4 | 11 |
To determine in patients undergoing on-pump cardiac surgery, if topical tranexamic acid (intra-pericardial) compared with intravenous tranexamic acid administration is associated with a non-inferior risk of in-hospital red blood cell transfusion.
| Participants | Topical Tranexamic Acid/Placebo | Intravenous Tranexamic Acid/Placebo |
|---|---|---|
| The Proportion of Patients In-hospital Who Receive Red Blood Cell Transfusions | 570 | 433 |
Analyzed using an ANCOVA model. In such a model, bags of blood product will be included as a dependent variable, whereas dose of tranexamic acid and treatment will be included as covariates.
| Participants | Topical Tranexamic Acid/Placebo | Intravenous Tranexamic Acid/Placebo |
|---|---|---|
| Blood Product Transfusions | 756 | 583 |
Analyzed with a binomial regression
| Participants | Topical Tranexamic Acid/Placebo | Intravenous Tranexamic Acid/Placebo |
|---|---|---|
| Re-operation for Bleeding or Tamponade | 63 | 46 |
Analyzed using an ANCOVA model.
| hour | Topical Tranexamic Acid/Placebo | Intravenous Tranexamic Acid/Placebo |
|---|---|---|
| Duration of ICU Stay | 24 (20 to 47) | 24 (20 to 46) |
A Cox proportional hazard model will be used to analyze the time to the first occurrence of the composite of death, non-fatal MI, or non-fatal stroke (MACE).
| Participants | Topical Tranexamic Acid/Placebo | Intravenous Tranexamic Acid/Placebo |
|---|---|---|
| MACE (Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke) | 40 | 31 |
The proportion of patients experiencing an in-hospital seizure (all).
| Participants | Topical Tranexamic Acid/Placebo | Intravenous Tranexamic Acid/Placebo |
|---|---|---|
| All Seizures | 4 | 14 |
Collected over Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)]. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Topical Tranexamic Acid/Placebo | 12/1,624 (0.7%) | 0/1,624 (0%) | 0/1,624 (0%) |
| Intravenous Tranexamic Acid/Placebo | 10/1,618 (0.6%) | 0/1,618 (0%) | 0/1,618 (0%) |
| Age, Continuous(years) | Topical Tranexamic Acid/Intravenous Placebo | Intravenous Tranexamic Acid/Topical Placebo | Total |
|---|---|---|---|
| Mean | 66.3 ± 8.8 | 65.7 ± 9.1 | 66 ± 9.0 |
| Sex: Female, Male(Participants) | Topical Tranexamic Acid/Intravenous Placebo | Intravenous Tranexamic Acid/Topical Placebo | Total |
|---|---|---|---|
| Female | 375 | 348 | 723 |
| Male | 1248 | 1270 | 2518 |
| Race/Ethnicity, Customized(Participants) | Topical Tranexamic Acid/Intravenous Placebo | Intravenous Tranexamic Acid/Topical Placebo | Total |
|---|---|---|---|
| White | 1535 | 1525 | 3060 |
| Asian | 62 | 64 | 126 |
| Aboriginal or American Indian | 12 | 8 | 20 |
| Other | 14 | 21 | 35 |
| Missing | 1 | 0 | 1 |
| Body mass index(kg/m^2) | Topical Tranexamic Acid/Intravenous Placebo | Intravenous Tranexamic Acid/Topical Placebo | Total |
|---|---|---|---|
| Mean | 28.9 ± 5.1 | 28.8 ± 5.0 | 28.8 ± 5.1 |
| History of Myocardial Infarction(Participants) | Topical Tranexamic Acid/Intravenous Placebo | Intravenous Tranexamic Acid/Topical Placebo | Total |
|---|---|---|---|
| Count of participants | 612 | 649 | 1261 |
| History of Diabetes(Participants) | Topical Tranexamic Acid/Intravenous Placebo | Intravenous Tranexamic Acid/Topical Placebo | Total |
|---|---|---|---|
| Count of participants | 486 | 471 | 957 |
| History of Stroke(Participants) | Topical Tranexamic Acid/Intravenous Placebo | Intravenous Tranexamic Acid/Topical Placebo | Total |
|---|---|---|---|
| Count of participants | 73 | 64 | 137 |
| History of Seizure(Participants) | Topical Tranexamic Acid/Intravenous Placebo | Intravenous Tranexamic Acid/Topical Placebo | Total |
|---|---|---|---|
| Count of participants | 15 | 6 | 21 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2019 to primary completion in Nov 2023, 50 months.
Results were first posted in Oct 2026, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid
Population Health Research Institute →